Home > Healthcare > Medical Devices > Diagnostic Devices > Gastrointestinal Diagnostics Market

Gastrointestinal Diagnostics Market Share

Report ID: GMI9711
Published Date: May 2024
Report Format: PDF

Download Free Sample

Gastrointestinal Diagnostics Market Share

The market is experiencing significant growth due to rising global prevalence of GI disorders like colorectal cancer and IBD, fuelled by factors such as aging populations and lifestyle changes. Key players, including diagnostic labs, healthcare providers, and medical device manufacturers, drive innovation with technologies like molecular diagnostics and AI-enabled tools, expanding diagnostic capabilities. Initiatives in preventive medicine and personalized healthcare are reshaping the landscape, emphasizing early detection and tailored treatment approaches. As demand for accurate GI diagnostics continues to escalate, market expansion, collaboration, and investment in advanced solutions are key strategies for industry players.

Gastrointestinal Diagnostics Market Companies

Prominent players operating in the gastrointestinal diagnostics industry include:

Abbott Laboratories
Beckman Coulter, Inc.
Becton, Dickinson and Company
bioMérieux
Bio-Rad Laboratories, Inc.
DiaSorin S.p.A
EKF Diagnostics Holdings plc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corporation
Meridian Bioscience
QIAGEN N.V.
R-Biopharm AG
Siemens Healthineers AG
Sysmex Corporation
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gastrointestinal diagnostics industry size was worth USD 4.8 billion in 2023 and is projected to expand at 4.6% CAGR from 2024 to 2032, due to the increasing prevalence of GI disorders, rising adoption of non-invasive diagnostic techniques, and growing healthcare expenditure.

The endoscopy test type segment in the gastrointestinal diagnostics industry recorded USD 1.7 billion in 2023, as it provides direct visualization of the gastrointestinal (GI) tract, allowing for accurate and precise diagnosis of various GI conditions such as ulcers, polyps, inflammation, and tumors.

The culture and sensitivity testing technology segment in the gastrointestinal diagnostics industry accounted for 33.6% share in 2023 and is projected grow at significant rate from 2024 to 2032, due to growing need for accurate and timely identification of causative agents to guide appropriate treatment.

North America gastrointestinal diagnostics market recorded USD 1.9 billion in revenue in 2023 and is projected to grow at 4.4% CAGR between 2024 and 2032, led by the increasing burden of gastrointestinal diseases, like colorectal cancer, inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and infectious gastrointestinal illnesses.